ARVINAS, INC. - 8-K Filing
Arvinas, Inc. entered into a $70 million upfront payment license agreement with Rigel Pharmaceuticals for exclusive global rights to commercialize VEPPANU (vepdegestrant), an FDA-approved breast cancer treatment. The deal includes up to $320 million in potential milestone payments and mid-teens to mid-20s tiered royalties on net sales, split evenly between Arvinas and Pfizer. (Items: 1.01 Entry into a Material Definitive Agreement, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $ARVN